Abstract 17P
Background
Breast Cancer is the most common yet preventable & treatable forms of cancer in the Philippines, hence a need to prioritize & strengthen organized screening programs to detect early & bridge to treatment to increase survival. The ACT Now PRIME CARE for Breast Cancer aims to detect breast cancer thru screening using integrated patient online education & self-evaluation with mobile clinic clinical breast exam, ultrasound, navigation to referral pathways for Centers with Medical Access Programs.
Methods
Women ages 40-60, were advised to register at actnow.philcancer.org.ph to access videos on breast health, cancer & self-exam. Patients' self-reported signs, symptoms & risk factors were triaged into high risk & low risk. Immediate scheduling of high-risk individuals to mobile clinic visit were done while low-risk individuals were advised to visit on a yearly basis. Patient education, Clinical Breast Exam & Ultrasound were performed. Both high risk & low risk groups were scheduled for teleconsultation or clinic visits. Suspicious breast findings were referred for immediate biopsy. Confirmed malignancy were referred to centers with medical access programs.
Results
Among women who completed the educational videos, 87% were evaluated to have good comprehension of the materials. Among 1,790 women screened, 277 were clinically high-risk patients & only 6 had breast ultrasound BIRADS 4-5. Two had negative biopsy results. Four had pending biopsy results. Two had confirmed positive early breast malignancy who were subsequently referred treatment. Turnaround time from work-up to treatment was 4 weeks. Among 1513 low risk women, majority have commitments to visit for screening once a year.
Conclusions
In a limited resource country, there's a need to strengthen community-based cancer screening, strengthen patient navigation & improve patients' awareness on available financial & medical access programs to improve compliance & survival. The ACT Now PRIME CARE is a pilot program to enhance education about breast health & cancer, capture cases in the community & provide immediate referral pathways to improve outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Philippine Cancer Society.
Funding
Philippine Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract